Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / Chongqing Chenan Biopharmaceutical
Entity

Chongqing Chenan Biopharmaceutical

Tracked across 1 events · 6 articles · First seen Aug 20, 2026 · Last active Aug 20, 2026

Sentiment
20
Attention
2
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
2 20
Business
Mankind Pharma licenses insulin analogues from Chenan
Mankind Pharma has entered into an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd., a China-based biopharmaceutical company, to commercialize two insulin analogues in India: Insulin Degludec and a combination of Insulin…
Impact: Chongqing Chenan Biopharmaceutical is the licensor, providing the insulin analogues to Mankind Pharma. The agreement expands its market reach into India and validates its biopharmaceutical assets.
Aug 20, 2026 · 6 articles
Key Actions (1)
100 Mankind Pharma signed exclusive licensing deal Chongqing Chenan BiopharmaceuticalMankind Pharma licenses...
ERGEN INTELLIGENCE
Track Chongqing Chenan Biopharmaceutical live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.